: Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data. Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study) / Catalano, Fabio; Brunelli, Matteo; Signori, Alessio; Rescigno, Pasquale; Buti, Sebastiano; Galli, Luca; Spada, Massimiliano; Masini, Cristina; Galuppini, Francesca; Vellone, Valerio Gaetano; Gaggero, Gabriele; Maruzzo, Marco; Merler, Sara; Vignani, Francesca; Cavo, Alessia; Bimbatti, Davide; Milella, Michele; Dei Tos, Angelo Paolo; Sbaraglia, Marta; Murianni, Veronica; Damassi, Alessandra; Cremante, Malvina; Maffezzoli, Michele; Llaja Obispo, Miguel Angel; Banna, Giuseppe Luigi; Fornarini, Giuseppe; Rebuzzi, Sara Elena. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - (2024). [10.2217/fon-2023-1068]
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)
Buti, SebastianoConceptualization
;Maffezzoli, MicheleInvestigation
;
2024-01-01
Abstract
: Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data. Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
